deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT03126591

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments

Sponsor: Eli Lilly and Company

Conditions Soft Tissue Sarcoma
Interventions Olaratumab Pembrolizumab (KEYTRUDA®)
Updated 38 times since 2017 Last updated: Aug 13, 2024 Started: Jul 3, 2017 Primary completion: May 6, 2021 Completion: Feb 21, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Soft Tissue Sarcoma and is currently completed. Eli Lilly and Company leads this study, which shows 38 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Jun 2022 · 12 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

38 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Nov 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. May 2023 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 33 earlier versions

  1. Sep 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Oct 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Sep 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Aug 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

  10. Jul 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  11. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1

  12. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  13. Apr 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  14. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

  15. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  16. Jan 2020 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  17. Dec 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1

  18. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

  19. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE1

  20. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

  21. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1

  22. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1

  23. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  24. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  25. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE1

  26. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  27. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1

  28. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  29. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  30. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  31. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  32. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  33. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
  • Merck Sharp & Dohme LLC
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations